Boulder’s MBio lands additional $1.5M in defense funding for rapid infection testing

BOULDER — Mbio Diagnostics Inc. received an additional $1.55 million from the U.S. Department of Defense this week to get a rapid infection testing device closer toward federal approval.

The Boulder-based company is developing a system to find specific biomarkers in a blood sample that would indicate the presence of a range of contagious diseases early in their incubation cycles.
In an emailed statement, chief operating officer Michael Lochhead said the system could be used for testing for COVID-19, but it would test for the presence of a C-reactive protein caused by inflammation instead of current tests, which check for COVID-19’s RNA with a sample.

MBio plans to file data to the U.S. Food and Drug Administration by March 2021.

SPONSORED CONTENT

Exploring & expressing grief

Support groups and events, as well as creative therapies and professional counseling, are all ways in which Pathways supports individuals dealing with grief and loss.

The Defense Department previously gave MBio $1.21 million for the project in February, according to federal contracting records. The company has received just more than $3.55 million in federal funding since 2012.